DarioHealth Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by DarioHealth Corp. (DRIO) on June 14, 2023. The filing discloses the entry into a material definitive agreement and material modifications to the rights of security holders regarding warrants and preferred stock issued in connection with a prior financing event.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on legal amendments to capital structure instruments rather than operational financial performance.
Material Changes and Agreements
- Warrant Amendment: On June 14, 2023, the Company entered into an agreement with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund, L.P. to amend warrants issued on May 1, 2023. The amendment removes the provision that would adjust the share count and exercise price (currently $3.334) in the event of a bona fide equity raise prior to September 30, 2023, at a price below the current exercise price.
- Preferred Stock Amendments: The Company filed amended Certificates of Designation for Series B, B-1, B-2, and B-3 Preferred Stock. These amendments:
- Removed the adjustment provision allowing conversion price reductions for equity sales below the conversion price (subject to a $3.00 floor) within 90 days of issuance.
- Removed the 19.99% non-waivable blocker from the Series B, B-2, and B-3 Certificates.
- Required stockholder approval for the issuance of dividend shares to Series B-2 holders.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or an outlook for future periods. The primary risk addressed is the modification of anti-dilution protections for warrant and preferred stock holders, which alters the potential dilution impact of future equity raises.
Investor Verification Checklist
- Verify the full text of the Warrant Amendment Agreement (Exhibit 4.1) to confirm the removal of anti-dilution triggers for equity raises before September 30, 2023.
- Review the amended Certificates of Designation (Exhibits 3.1 through 3.4) to confirm the removal of the 19.99% blocker and conversion price adjustment provisions.
- Confirm the current exercise price of the warrants remains at $3.334 post-amendment.
- Assess the impact of these amendments on the Company's ability to raise capital at prices below the current exercise price without triggering dilution adjustments.